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Abstract
Gastric cancer remains one of the most common cancers worldwide and one of the leading cause for cancer-
related deaths. Due to the high frequency of metastasis, it is still one of the most lethal malignancies in which
kinds of signaling pathways are involved in. The Roundabout (ROBO) receptors and their secreted SLIT glycoprotein
ligands, which were originally identified as important axon guidance molecules, have implication in the regulation
of neurons and glia, leukocytes, and endothelial cells migration. Recent researches also put high emphasis on the
important roles of the Slit-Robo pathway in tumorigenesis, cancer progression and metastasis. Herein we provide a
comprehensive review on the role of these molecules and their associated signaling pathway in gastric and other
gastrointestinal cancers. Improved knowledge of the Slit-Robo signaling pathway in gastric carcinoma will be useful
for deep understanding the mechanisms of tumor development and identifying ideal targets of anticancer therapy
in gastric carcinoma.
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Background
Gastric cancer (GC) is the fourth-most-common cancer
globally and the second-leading cause of the cancer deaths
[1]. The potential risk factors include Helicobacter pylori
(H. pylori) and EBV infection, high-salt and low-vegetable
diet, smoking, chronic gastritis with glandular atrophy and
intestinal metaplasia, and the most important factor is
genetic alterations [2]. Currently, the main treatment op-
tion is the gastrectomy combined with chemotherapy and
radiation therapy protocols. Unfortunately, survival of
patients with advanced GC treated with palliative chemo-
therapy remains low. The poor prognosis associated with
GC is mainly related with high frequency of metastasis.
Tumor cell motility and invasion play fundamental roles
in cancer metastasis. Therefore, an in-depth understand-
ing of molecular bases of the GC is required.
GC is proposed to result from the complex interplay be-
tween genetic and environmental factors at the gastric
mucosa level that deregulates cell potentially oncogenic
signaling pathways, leading to GC development [3, 4]. Pre-
vious studies in GC revealed multiple oncogenic signaling
pathways such as Wnt/β-catenin, nuclear factor-κB,
Hedgehog, Notch and epidermal growth factor receptor
are implicated in gastric carcinogenesis [5]. Activation of
these signaling cascades leads to acquisition of malignant
phenotypes including increased cell proliferation, evasion
of apoptosis and enhanced invasiveness. Improved know-
ledge of these signaling pathways will help to understand
the molecular mechanisms in GC and identify novel tar-
gets for anticancer drug development. In this brief review,
the involvement of the Slit-Robo signaling pathway and its
biological significance in gastrointestinal cancers will be
summarized.
The main components of Slit-Robo pathway
The Roundabout (Robo) gene encodes a transmembrane
receptor that was firstly identified in Drosophila [6]. Six
years later, the Drosophila SLIT protein was identified as
the ligand for ROBO receptor [7]. SLIT proteins are
secreted glycoproteins that mediate their functions by
binding to the ROBO. There are three ROBOs (ROBO1,
ROBO2 and ROBO3) and a single SLIT in Drosophila [8].
Thereafter, three SLITs (SLIT1, SLIT2, SLIT3) and four
different ROBOs (ROBO1/DUTT1, ROBO2, ROBO3/
RIG-1, ROBO4/Magic Roundabout) members have been
described in human [9, 10].
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SLIT1–3 are expressed in the nervous system and in
most organs [11]. The most commonly studied member is
SLIT2. It is known to regulate many aspects of tissue mor-
phogenesis and cell function, including cell migration, pro-
liferation, adhesion and death [12]. Although the genes
overlap, their expression patterns and functions are distinct.
SLIT1 is specific to the brain, and SLIT2 and SLIT3 are
expressed in the brain as well as other tissues [13]. SLITs
are characterized by four distinct domains. There are 4
leucine-rich repeats (LRR) domains at the N-terminus,
termed D1-D4. This region is followed by six EGF-like se-
quences (EGF), a laminin-G domain and a C terminus with
a cysteine-rich knot [14, 15]. Detailed structure-function
studies have shown that the second LRR domain plays an
important role in binding to ROBO proteins [16].
ROBO is a single-pass, transmembrane receptor belong-
ing to the immunoglobulin superfamily. In mammals,
ROBO1-3 is expressed in many tissues during develop-
ment and particularly in the nervous system [17–19]. The
latest member of this family ROBO4, also called magic
roundabout, was originally thought to be expressed mainly
by endothelial cells [20, 21]. ROBO1 and ROBO4 are two
receptors of the secretory protein SLIT2. All ROBOs, with
the exception of ROBO4, share a common extracellular
domain structure of five immunoglobulin-like (Ig) motifs
followed by three fibronectin type 3 (FNIII) domains and
four conserved cytoplasmic (CC) domains, expressed in
different combinations within the ROBO receptor family
[22]. The cytosolic ROBO domains are poorly conserved,
with the notable exception of several conserved linear mo-
tifs, CC0-CC3, which occur in different combinations in
different ROBOs. The intracellular domains of ROBO1
and ROBO2 share the same conserved cytoplasmic motifs
(CC0, CC1, CC2 and CC3). The CC1 motif is absent in
ROBO3. ROBO4, which has the lowest homology with
other ROBO family members, contains only two IG and
FNIII domains along with one CC motif, CC2 [23]. The
IG1 and IG2 of ROBO is essential for the Slit–Robo inter-
action [24].
Biochemical studies show that the interaction between
SLIT and ROBO involves the highly conserved second LRR
domain (D2) of SLIT and the IG1 domain of ROBO, while
IG2–IG5 and all FN3 domains of ROBO1 appear to be dis-
pensable for binding [16, 23, 25, 26]. Substantial evidence
has been accumulated that Slit-Robo signaling strictly
requires heparin sulfate (HS) proteoglycans [27, 28]. HS
proteoglycans have been shown to stabilize the relatively
weak Slit-Robo interaction [29].
The physiological function of Slit-Robo pathway
Slit-Robo signaling was first established as an extracellular
signature to guide axon path finding, promote axon
branching and control neuronal migration. The interaction
of SLIT and ROBO proteins is crucially involved in the
development processes of various vital organs such as
breast, lung, liver, kidney, eye and reproductive systems
[24]. Function of Slit-Robo signaling is influenced by bind-
ing of intracellular factors to the cytoplasmic domains of
ROBO. The cytosolic domains of ROBOs are catalytically
inactive. ROBO activation at the cell surface is then trans-
lated within the cell by a number of signaling cascade
events. Although it is best known as a conserved repellent
cue for axon guidance during the development of the cen-
tral nervous system, its other functions are becoming in-
creasingly studied. This section will introduce the various
physiological functions of Slit-Robo signaling.
The role of Slit-Robo in nervous system development
The central nervous system (CNS) develops along a bilat-
eral axis of symmetry located at the midline [30]. During
development, the ventral midline or floor plate acts as an
organizer through the secretion of diffusible proteins, which
control the growth of axons and dendrites and the migra-
tion of neurons across the midline [30, 31]. Slit-Robo sig-
naling was first established as extracellular signature axon
guidance [8, 32]. They function as a repulsive cue with an
evolutionarily conserved role in preventing axons from mi-
grating to inappropriate locations during the assembly of
the nervous system [8]. Furthermore, the Slit-Robo inter-
action has a similar function during the development of
other processes in the nervous system including formation
of the olfactory tract, optic chiasm, optic tract, forebrain
and hindbrain [33].
The role of Slit-Robo in cell motility
Slit-Robo signaling has been shown to control the migra-
tion of several neuronal subtypes in mice including cortical
interneurons [34, 35], cerebellar granule neurons [36, 37]
and inferior olivary neurons [38]. At the subcellular level,
novel data suggest that SLITs control neuronal migration
by influencing cell polarity. Calcium (Ca2+) signaling and
Rho GTPases are known to modulate the radial migration
of cortical neurons and cerebellar granule cells [39, 40]. In
order to direct changes in cell motility, the binding of SLIT
to the ROBO receptor leads to reorganization of the actin
cytoskeleton. The binding of the SLITs modified the
cytoplasmic domains of the ROBO receptors. Actin
polymerization is regulated by several adaptor proteins that
can bind to the cytoplasmic motifs of the ROBO receptors.
In drosophila, the two proteins Ableson tyrosine and En-
abled (Ena) mediate cytoskeletal remodeling downstream of
Slit-Robo signaling [41]. In mammals, small GTPases of the
Rho family, such as RhoA, Rac1 and Cdc42, are key regula-
tors of actin cytoskeletal dynamics [42]. These proteins
switch from an inactive GDP-bound state to an active
GTP-bound state and are regulated by the GTPase-
activating proteins (GAPs) and the guanine nucleotide-
exchange factors (GEFs). GEFs activate Rho GTPases while
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GAPs inactivate them by inducing GTP hydrolysis. The
binding of the ligand modifies the cytoplasmic domains of
the ROBO receptors, which leading to the recruitment to
the intracellular domain of ROBO1 interacts with Slit-Robo
GAP1 (srGAP1) and leads to the inactivation of Cdc42 and
a modest activation of RhoA and Rac [43, 44]. GTP-bound
RhoA promotes the formation of actin stress fibers and
focal adhesions and mediated cell repulsion. However,
GTP-bound Cdc42 and Rac lead to cell attraction and pro-
mote the formation of filopodia and lamellipodia, respect-
ively [45]. Thus, Slit2-Robo signaling dynamically regulates
rearrangements of the actin cytoskeleton and influences
multiple cellular processes [46].
The role of Slit-Robo in angiogenesis
Slit-Robo signaling also has important roles in regulating
both non-pathological and pathological angiogenesis.
SLIT3, ROBO1 and ROBO4 are expressed by endothelial
cells. ROBO4 in particular is exclusively expressed by endo-
thelial cells [21, 47]. Indeed, morpholino-mediated knock
down of ROBO4 leads to asynchronous intersomitic vessel
sprouting, resulting in a reduction and misdirection of
intersomitic vessels [48]. Recently identified ROBO4 is the
key mediator of Slit-Robo mediated developmental and
pathological angiogenesis. ROBO4 is expressed specially in
vascular endothelial cells and maintains the vascular integ-
rity via either SLIT2 dependent or SLIT2 independent
manner. On the contrary, it promotes the pathological
angiogenesis by involving different signaling arm(s)/un-
known ligand(s) [49].
Other physiological roles of Slit-Robo pathway
Slit-Robo signaling can regulate other cellular processes in-
volved in cell growth. It can inhibit hepatocyte growth fac-
tor (HGF), stromal derived factor-1 (SDF-1) and β-catenin
activity [50–52]. Furthermore, Slit-Robo signaling axis is
also extensively involved in myogenesis [53], kidney induc-
tion [54], heart tube formation [55], leukocyte migration
[13], periodontitis [56], and vascular injury [56].
The deregulated Slit-Robo pathway in
gastrointestinal cancers
Apart from physiological functions, Slit-Robo interactions
are involved in many pathological cellular processes,
including cell cycle, apoptosis, cell adhesion, motility,
angiogenesis and invasion, which are important for tumori-
genesis [57]. There is evidence that loss of ROBO1 in mice
induces tumorigenic. Most ROBO1-knockout mice exhibit
postnatal morbidity, but surviving mice suffer from bron-
chial hyperplasia and focal dysplasia [58]. The current data
indicate that Slit-Robo pathways differentially modulate in-
vasion and migration, which varies according to signaling
and type of cancers. The first link between Slit-Robo signal-
ing and the cancer was reported by Sundaresan [59].
Although the involvement of Slit-Robo signaling in tumor
development has been widely implicated, the biological sig-
nificance and molecular mechanisms of Slit-Robo signaling
in the initiation of gastrointestinal cancers are largely un-
determined. Gastrointestinal cancers refer to malignant
conditions of the gastrointestinal tract and accessory
organs of digestion, including the esophagus, stomach,
biliary system, pancreas, small intestine, large intestine,
rectum and anus.
Gastric adenocarcinoma
The activation or suppression of the Slit-Robo pathway
modulates several oncogenic signaling pathways that are as-
sociated with the development and progression of cancer
[60, 61]. In 2003, Wang et al. demonstrated the angiogen-
esis promoting function of Slit-Robo signaling and evalu-
ated the significance of this pathway in the pathogenesis of
cancers. They examined human samples of different carcin-
omas and found in gastric squamous carcinoma samples,
SLIT2 was expressed in the cancerous tissues, but not in
the nearby regions of apparently normal tissues. The posi-
tive staining of SLIT2 was found in 38 gastric carcinomas.
Their results have showed SLIT2 can attract vascular endo-
thelial cells and promote tumor-induced angiogenesis. Fur-
thermore, they demonstrated the neutralization of ROBO1
reduced the microvessel density and the tumor mass of hu-
man malignant melanoma A375 cells in vivo [3, 62].
Meanwhile, Wang et al. revealed that the NF-κB/
POU2F2/SLIT2/ROBO1 network might play an essential
role in GC metastasis. POU2F2 promoted GC metastasis
by a positive regulation of ROBO1. The interaction be-
tween NF-κB and the SLIT2/ROBO1 pathway linked by
POU2F2 contributed to GC metastasis [63].
Tie et al. have shown that GC metastasis is associated
with the downregulation of a specific set of miRNAs, in-
cluding miR-218-1, a miRNA hosted in an intron of the
SLIT3 gene, which directly inhibits ROBO1 expression
using both in vitro and in vivo approaches. They present a
model in which the acquisition of metastatic propensity oc-
curs as a result of the downregulation of miR-218-1 and an
upregulation of ROBO1 [64]. Furthermore, miR-218 may
also regulate ROBO1 function during angiogenesis [65].
Recent data from our laboratory showed a potential
co-regulation of srGAP1 (Slit-Robo GTPase activating
protein1) in GC (data not shown here). srGAP1 is a
downstream component of Slit-Robo signaling. Secretory
glycoprotein SLIT2 interacts with its membrane receptor
ROBO1 leading to the activation of srGAP1. Currently it
is unclear whether these genes are differentially regu-
lated based on tumor type or stage, but mounting evi-
dence suggests that changes in the expression of these
genes play important roles in regulating tumor progres-
sion. We also identified ROBO1 was significantly up-
Huang et al. BMC Cancer  (2015) 15:950 Page 3 of 9
regulated in some GC cell line when compared to normal
gastric epithelium cells.
On the contrary in 2013, Zhang et al. described the ex-
pression pattern of SLIT2 in GC. Immunohistochemistry
(IHC) staining revealed that SLIT2 was found decreasingly
expressed in advanced-stage GC tissues when compared
with early-stage GC [66]. Subsequently, they investigated
the roles of SLIT2 in GC. They generated the SLIT2-
knockdown gastric cell model and found SLIT2 knock-
down promoted GC cell growth and metastasis in vitro and
in vivo. SLIT2 knockdown increased GC cell growth in
monolayer and soft agar/Matrigel 3D culture. SLIT2-
knockdown cells formed larger tumors and produced more
peritoneal metastatic nodules in nude mice. Subsequently,
they suggested that knockdown of SLIT2 activates AKT,
enhances anti-apoptotic ability and activates β-catenin
oncogenic signaling. They suggested a tumor-suppressor
role of SLIT2 in GC [67].
In addition, a research group found ROBO1 and
ROBO2 frameshift mutations in both GC and colorectal
cancer (CRC). Frameshift mutations of ROBO1 and
ROBO2 genes and loss of ROBO1/2 expression in GC
and CRC suggested that both genes might play roles in
the pathogenesis of GC and CRC [68]. Meanwhile,
ROBO1 or ROBO2 expression is frequently lost in many
cancers, including head/neck, breast, lung, kidney and
uterine cervix cancers, and is associated with methylation
and loss of heterozygosity of these genes [69–71]. These
data suggest that both ROBO1 and ROBO2 are potential
tumor suppressor genes.
The Cancer Genome Atlas (TCGA) project described a
comprehensive molecular evaluation of primary gastric
adenocarcinomas [72]. According to the cBioPortal for
Cancer Genomics which has comprehensively summarized
the TCGA data, the SLIT2, ROBO1 and srGAP1 gene show
19 % (47/258), 13 % (31/258) and 12 % (29/258) cases with
alterations. The alterations include somatic mutations, copy
number changes (gene amplification or deletion) and
mRNA expression change [73, 74].
Overall, the functional study of Slit-Robo pathway in
GC seems very contradictory by different research groups
and further studies will be performed to elucidate the
complex signaling pathway in gastric tumorigenesis
(Fig. 1).
Hepatocellular carcinoma (HCC)
Avci et al. quantified Slit-Robo transcripts in HCC cell
lines, normal and tumor tissues from liver, and suggested
that the expression of Slit-Robo genes were regulated in
hepatocarcinogenesis. Slit-Robo expression predicted
AFP-dependent subgrouping of HCC cell lines and
ROBO1 was found to be significantly overexpressed in
HCC [75]. Ito et al. identified of ROBO1 as a novel hepa-
tocellular carcinoma antigen and a potential therapeutic
and diagnostic target. They found ROBO1 was highly
expressed in HCC, whereas it showed only a limited dis-
tribution in normal tissues. Strikingly, the ectodomain of
ROBO1 was detected in sera from HCC patients [76].
Subsequently, a novel function for SLIT and ROBO in the
inhibition of growth factor-mediated epithelial cell motil-
ity and morphogenesis has been disclosed. The Slit-Robo
interaction inhibits hepatocyte growth factor (HGF)/
MET-induced tumor cell migration and invasion [52].
Colon cancer
Although efforts have been made to elucidate the role of
Slit-Robo signaling in CRC, the results are also contradict-
ory [77–79]. Zhou et al. found that the N-terminal domain
of SLIT2 could induce malignant transformation of colo-
rectal epithelial cell and tumor metastasis. They found
that engagement of ROBO1 by SLIT2 recruits Hakai to E-
cadherin, culminating in E-cadherin ubiquitination and
lysosomal degradation [78]. Previously, they have reported
elevated expression of SLIT2 in human colorectal carcin-
oma tissues and cell lines [62]. Using cDNA microarray, a
significant upregulation of ROBO1 was found in colorec-
tal carcinoma tissues [80]. Furthermore, knockdown of
endogenous ROBO1 or specific blockade of SLIT2 bind-
ing to ROBO1 prevented E-cadherin degradation and
reversed EMT (epithelium mesenchymal transition),
resulting in diminished tumor growth and liver metastasis.
In colorectal carcinoma patients, the overexpression of
SLIT2 and ROBO1 was significantly associated with an
increased metastatic risk and poorer overall survival in
colorectal carcinoma patients.
On the contrary, Dallol et al. reported that SLIT2 is an
excellent candidate tumor suppressor gene in CRC and
frequently inactivated and suppresses the growth of CRC
cells [77]. Yu et al. found the expression levels of miR-218,
SLIT2 and SLIT3 in CRC tissues were decreased and
miR-218 expression was significantly associated with
TNM stage, lymph node metastasis and differentiation
[81]. Subsequently, Chen et al. found SLIT2 suppresses
colon tumor metastasis, and exerts suppressive activity
against CRC metastasis by restraining AKT signaling and
EMT [79]. Recently, Huang et al. found that the USP33
mediates Slit-Robo signaling in inhibiting CRC cell migra-
tion [82].
Esophageal cancer
In esophageal cancers, SLIT2 is a migration suppressor for
ESCC (esophageal squamous cell carcinoma) via inhibition
of srGAP–Cdc42 signaling and membrane localization of
p-FAK and p-Paxillin. Tseng et al. found that 31.8 % (49 of
54) of tumors from ESCC patients showed low expression
of SLIT2 protein, which correlated with poor overall sur-
vival and disease-free survival. They also demonstrated that
promoter hypermethylation of SLIT2 is responsible for low
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expression level in ESCC. SLIT2 overexpression decreased
Cdc42 activity in ESCC cells, while knockdown of SLIT2
facilitated the translocation of p-FAK and p-Paxillin to per-
ipheral actin cytoskeleton. Cdc42, p-FAK, and p-Paxillin
may be involved in SLIT2-mediated suppression of migra-
tion [83]. Subsequently, in ESCC, Jiang et al. found miR-
1179 promotes cell invasion through SLIT2/ROBO1 axis.
Down-regulation of miR-1179 suppressed cell invasion in
vitro with an increasing level of SLIT2 and ROBO1. Be-
sides, the upregulation of SLIT2 decreased cell invasiveness
through ROBO1 [84].
Pancreatic cancer
Unbiased analysis of the transcriptional network govern-
ing the angiogenic switch in human pancreatic cancer
identified ROBO1 and SLIT1 as putative proangiogenic
genes [85]. In pancreatic cancer, Fu et al. found the
miRNA-218 and Robo1 signaling axis may contribute to
the lymphatic metastasis of pancreatic cancer. They also
first demonstrated downregulation of miRNA-218 and
upregulation of ROBO1 in pancreatic cancer [86]. Fur-
thermore, Tang et al. found that the Slit-Robo signaling
genes were frequently altered in pancreatic cancer [60].
Subsequently, SLIT2 was found to inhibit leukocyte mi-
gration in the gradient of monocyte chemotactic protein-1
(MCP-1) in an in vitro pancreatic cancer model [87].
Intestinal cancer
In intestinal tumorigenesis, Zhang et al. employed sev-
eral complementary mouse models to clarify the onco-
genic function in intestinal tumorigenesis. They showed
that SLIT2 and ROBO1 are overexpressed in intestinal
tumors. SLIT2-ROBO1 signaling promoted tumorigen-
esis and tumor growth and this was mediated in part
through activation of the Src signaling, which then
down-regulated E-cadherin, thereby activation Wnt/β-
catenin signaling [88]. Thus, SLIT2-ROBO1 signaling
was proposed to play oncogenic role in intestinal
tumorigenesis.
Fig. 1 The schematic representation of Slit-Robo signaling pathway in gastric tumorigenesis
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The Slit-Robo signaling pathway in some other
solid tumors
In addition, several SLITs and ROBOs are aberrantly
expressed during the development of breast [89–91], lung
[10, 92], ovarian [93–95], cervical [96] and prostate cancer
[97]. In this review, we also briefly summarized the aber-
rant Slit-Robo pathway in breast and lung tumorigenesis.
The Slit-Robo signaling pathway in breast cancer
In breast cancer, Slit-Robo has antitumor activity. Most
breast tumors have low expression of Slit-Robo and its
higher expression is correlated with increased survival
rate in cancer patients, whereas low SLIT2 expression is
associated with poor survival and increased metastasis
[89, 90, 98]. Ectopic SLIT2 expression in breast cancer
cells inhibits tumor cell migration and tumor growth in
engrafted mice models through a mechanism implicating
β-catenin modulation [51]. In breast cancer, SLIT2 blocks a
whole host of SDF1-induced signaling involved in motility
such as the activation MAP kinase or focal adhesion com-
ponents [50]. Similarly, overexpression of Slit-Robo in
breast cancer leads to down-regulation of CXCR4 and sup-
pression of tumour growth [90]. Recently, Chang et al.
demonstrated that activation of Slit-Robo inhibits activation
of β-catenin by inhibiting AKT, thereby preventing trans-
location of cytosolic β-catenin to the nucleus of the fibro-
blast cells [99]. Furthermore, in breast cancer cells, SLIT2
also inhibits tumor cell migration by affecting the direction
of migration through the deubiquitylating enzyme USP33
[100].
The Slit-Robo signaling pathway in lung cancer
In lung cancer, the expression of SLIT2 is suppressed
[10, 92, 101]. Suppression of SLIT2 was associated with
Table 1 Summary of expression and function of SLIT1, SLIT2, SLIT3, ROBO1, ROBO2 and ROBO4 in cancers
Gene Expression in cancers Function Metastasis References
SLIT1 Upregulation Prostate cancer Increased expression in prostate tumors [97]
SLIT2 Downregulation Colorectal cancer Tumour suppress Suppress [10, 79, 80]
Esophageal squamous cell
carcinoma
Correlated with poor overall survival Suppress [84]
Intestinal tumors Promotes intestinal tumorigenesis [88]
Breast cancer Tumour suppressor and low expression is associated with poor
survival and increased metastasis
Suppress [89, 90, 98]
[51]
Lung cancer Tumour suppressor Suppress [10, 92, 101]
[102]
Advanced gastric cancer Knockdown of SLIT2 in gastric cancer cells promotes cell growth
and metastasis in vitro and in vivo
Suppress [66, 67]
Upregulation Colorectal cancer Induce malignant transformation of colorectal epithelial cell and
tumor metastasis
Promote [78] [62]
SLIT3 Downregulation Colorectal cancer SLIT3 is frequently methylated in colorectal cancers [10, 77]
Breast cancer SLIT3 methylation in breast tumours correlated with reduced
SLIT3 expression
[10]
Liver cancer SLIT3 was significantly down-regulated in cell lines with high-AFP
background
[75]
ROBO1 Downregulation Breast cancer A high frequency of allele loss [18] [69]
Lung cancer A high frequency of allele loss [69]
Prostate cancer ROBO1 expression was significantly reduced in prostate tumors [97]
Upregulation Gastric cancer SLIT2 interacted with ROBO1 to promote gastric cancer invasion Promote [62, 64] [63]
Liver cancer Overexpressed in and shed into serum for prediction of tumor
stage and differentiation status
[76] [75]
Intestinal tumors Promotes intestinal tumorigenesis Promote [88]
Pancreatic cancer Contribute to the lymphatic metastasis of pancreatic cancer Promote [86]
Colorectal cancer ROBO1 was significantly associated with an increased metastatic
risk and poorer overall survival in colorectal carcinoma patients
Promote [77]
ROBO2 Upregulation Liver cancer ROBO2 were significantly up-regulated cell lines with high-AFP
background
[75]
ROBO4 Downregulation Liver cancer ROBO4 could discriminate poorly differentiated HCC from other
subgroups
[75]
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a poor patient survival in late-stage diseases [102]. Stimulat-
ing SLIT2 expression increased the level of E-cadherin
caused by attenuation of its transcriptional repressor
SNAI1. Conversely, knocking down SLIT2 expression in-
creased cell migration and reduced cell adhesion through
coordinated deregulation of β-catenin and E-cadherin/
SNAI1 in the AKT/GSK3β/βTrCP pathway [102]. Further-
more, USP33 was identified to regulates SLIT signaling by
stabilizing ROBO1 and was required for SLIT inhibition of
lung cancer cell migration [103]. These results suggested
that SLIT2 suppresses lung cancer progression.
Conclusions
In conclusion, the literatures concerning Slit-Robo signal-
ing functions in tumorigenesis are controversial (summa-
rized in Table 1). In most of the cancer types, Slit-Robo
acts as a tumor suppressor by inhibiting cell invasion and
migration [12, 50, 92, 104–107], except in some gastro-
intestinal cancers [78].
However several issues should be addressed in the follow-
ing study of Slit-Robo pathway in GC. First, the key mem-
bers in SLIT family and ROBO family which are involved in
GC should be identified including expression and mutation
status. Due to the detailed mechanism of Slit-Robo signal-
ing exerting its function in gastric tumorigenesis is not
clearly and fully understood. Thus the cytoskeleton
changes, cell migration and invasion, angiogenesis, prolifer-
ation and apoptosis, crosstalk pathways linking to Slit-Robo
signaling need to be elucidated. Second, although a hypo-
thetical signal transduction has been proposed in Slit-Robo
signaling, we still need to comprehensively investigate how
this pathway is regulated. The most important issue is there
are still no targetable molecules which can efficiently target
the Slit-Robo pathway. Therefore, vast possibilities exist for
carrying out additional basic research in this direction to
development efficient targeted anticancer therapies.
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